Group 1: Investor Relations Activity Overview - The investor relations activity was an earnings briefing held on May 7, 2025, from 15:00 to 17:00 [3] - The event was conducted online via the Shanghai Securities News and China Securities Network [3] - Key participants included the Chairman and General Manager, CFO, and sponsoring representatives [4] Group 2: Sales and Production Capacity - The company reported a decline in sales revenue for 2024 and discussed strategies to absorb increased production capacity from the new factory [3] - Strategies to manage new capacity include developing new products for existing customers, increasing demand in the domestic special medical food sector, and expanding into overseas markets [4] Group 3: Research and Development Progress - The project on "Preparation Method and Industrialization Research of High Purity L-Leucine" is currently in the industrialization verification stage, with expected sales in the second half of the year [4] - The histidine project is also in the industrialization verification phase, with significant progress noted in the establishment of a production line [5] Group 4: Supplier Relations and Market Impact - The acquisition of Japan's Kyowa by Meihua Group may have implications for the supply of raw materials, but the company believes the impact will be minimal due to a sufficient supply of amino acid raw materials [5] - The company is focused on enhancing its technological innovation and overall strength to mitigate potential supply chain risks [5]

Investment Rating - The investment rating for Wuxi Jinghai is "Outperform" (maintained) [1] Core Views - The company reported a sales recovery in both domestic and international markets, with an increase in the proportion of high-value-added products [6] - The first quarter of 2025 showed a revenue of 104 million yuan, a year-on-year increase of 13.0% and a quarter-on-quarter increase of 21.0% [6] - The net profit attributable to the parent company for Q1 2025 was 19.13 million yuan, reflecting a year-on-year growth of 30.4% and a quarter-on-quarter growth of 308.2% [6] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 368 million yuan, with a year-on-year growth rate of 8.7% [5] - The net profit attributable to the parent company for 2025 is estimated at 58 million yuan, with a year-on-year growth rate of 34.3% [5] - Earnings per share for 2025 is projected to be 0.74 yuan [5] - The gross profit margin for Q1 2025 was 32.2%, an increase of 1.4 percentage points year-on-year [6] - The return on equity (ROE) for 2025 is expected to be 8.2% [5] Revenue and Profitability Insights - The growth in revenue is primarily driven by high-priced raw materials and culture medium products, with domestic sales recovering as inventory depletion ends [6] - The company has seen a decrease in raw material prices, contributing to an increase in the gross profit margin [6] - The product mix has shifted towards higher-margin raw materials and culture medium products, which have gross margins of 36.0% and 42.2%, respectively [6] Future Outlook - The existing fields are expected to recover in 2025, with new production lines anticipated to contribute significantly in 2026 [6] - The company is focusing on expanding into overseas markets and special medical foods following the completion of its fundraising projects [6] - The estimated net profits for 2025-2027 are adjusted to 58 million, 80 million, and 100 million yuan, respectively [6]

无锡晶海氨基酸股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 会议召开和出席情况 （一）会议召开情况 证券代码：836547 证券简称：无锡晶海 公告编号：2025-043 3.回避表决情况： 会议应出席监事 3 人，出席和授权出席监事 3 人。 1. 会议召开时间：2025 年 4 月 29 日 2. 会议召开地点：公司会议室 3. 会议召开方式：现场 4. 发出监事会会议通知的时间和方式：2025 年 4 月 25 日以电话方 式发出 5. 会议主持人：沈洪 6. 召开情况合法、合规、合章程性说明： 二、 议案审议情况 （一） 审议通过《关于公司<2025 年第一季度报告>的议案》 1.议案内容： 根据《北京证券交易所上市公司业务办理指南第6号——定期报 告相关事项》《北京证券交易所股票上市规则》等相关规定，结合公 司2025年第一季度实际经营情况，编制了公司2025年第一季度报 告。公司2025年第一季度报告的编制程序、内容、格式符合中国证 监会 ...

证券代码：836547 证券简称：无锡晶海 公告编号：2025-042 无锡晶海氨基酸股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 会议召开和出席情况 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合有关法律法规、规范 性文件和《公司章程》的规定，所做决议合法有效。 （一）会议召开情况 1.会议召开时间：2025 年 4 月 29 日 2.会议召开地点：公司会议室 3. 会议召开方式：现场 4. 发出董事会会议通知的时间和方式：2025 年 4 月 25 日以电话方 式发出 5. 会议主持人：李松年 6. 会议列席人员：监事会主席沈洪、监事王丰、职工代表监事曹一 岗、财务总监兼董事会秘书陈向红 （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、 议案审议情况 （一） 审议通过《关于公司<2025 年第一季度报告>的议案》 1.议案内容： 根据《北京证券交易所上市公司业务办理指南第 6 号——定 ...

Financial Performance - Net profit attributable to shareholders rose by 30.39% to CNY 19,132,669.99 for Q1 2025, up from CNY 14,673,681.53 in the same period last year[10] - Operating revenue for Q1 2025 reached CNY 104,177,997.52, reflecting a growth of 13.04% compared to CNY 92,158,215.06 in Q1 2024[10] - The company reported a significant increase in investment income by 269.97% to CNY 1,403,223.67, due to higher returns from structured deposits and low-risk investments[13] - The total comprehensive income for Q1 2025 was ¥19,132,669.99, compared to ¥14,673,681.53 in Q1 2024, indicating a strong performance[38] - Operating profit for Q1 2025 was ¥22,329,633.86, an increase of 28.3% from ¥17,416,882.06 in Q1 2024[38] Cash Flow - The net cash flow from operating activities increased by 29.86% to CNY 19,967,691.32, compared to CNY 15,376,630.73 in the previous year[10] - Cash inflow from operating activities increased to CNY 109,889,613.19 in Q1 2025, up from CNY 91,034,853.10 in Q1 2024[43] - The company reported a net cash outflow from financing activities of CNY -26,347,107.13 in Q1 2025, contrasting with a net inflow of CNY 22,068,986.34 in Q1 2024[42] - Cash flow from investment activities increased by 118.53% to 38,617,287.68 RMB, driven by the redemption of structured deposits and the issuance of bank acceptance bills for fixed asset payments[14] - The company received CNY 20,679,280.00 in other operating cash in Q1 2025, a substantial increase from CNY 1,000,130.80 in Q1 2024[43] Assets and Liabilities - Total assets increased by 5.68% to CNY 849,583,307.77 as of March 31, 2025, compared to CNY 803,935,578.14 at the end of 2024[10] - The company's asset-liability ratio (consolidated) improved to 19.72% from 17.84% year-on-year[10] - Current liabilities rose to ¥161,800,354.49 from ¥137,598,061.35, reflecting an increase of approximately 17.6%[32] - Total liabilities increased to ¥167,570,141.98 from ¥143,457,042.34, marking a growth of around 16.8%[33] - Shareholders' equity rose to ¥682,013,165.79 from ¥660,478,535.80, showing an increase of about 3.3%[33] Shareholder Information - Major shareholder Li Songnian holds 59.87% of the total shares, amounting to 46,512,000 shares[20] - The total number of ordinary shares remained at 77,688,000, with 45.83% being unrestricted shares[19] - The total number of shares held by major shareholders is 57,642,490, representing 74.20% of the total shares[21] Operational Insights - The company plans to continue expanding its market presence, focusing on both domestic and international sales[13] - The company is in the process of merging its wholly-owned subsidiary Wuxi Jinghong Biotechnology Co., Ltd. into Wuxi Jinghai, with the merger expected to complete soon[25] - The company expects to sell goods worth 5,000,000 yuan to related party Wuxi Jingyang Biotechnology Co., Ltd. in 2025, with no sales recorded as of the reporting period[25] Other Financial Metrics - The gross profit margin showed slight improvement due to enhanced cost control measures[13] - Research and development expenses rose to ¥4,502,779.43 in Q1 2025, compared to ¥3,732,394.90 in Q1 2024, marking a 20.6% increase[37] - Tax expenses for Q1 2025 were ¥3,164,246.82, up from ¥2,673,200.53 in Q1 2024, reflecting a 18.3% increase[38] - The company reported a 71.39% decrease in tax payments to 783,501.04 RMB, attributed to reduced income tax liabilities from last year's profit decline[14]

证券代码：836547 证券简称：无锡晶海 公告编号：2025-041 无锡晶海氨基酸股份有限公司 2024 年年度报告说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 说明会类型 无锡晶海氨基酸股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日在北京证券交易所信息披露平台（www.bse.cn）披露了 《2024 年年度报告》（公告编号：2025-030）及《2024 年年度报告 摘要》（公告编号：2025-031），为方便广大投资者更深入了解公司 2024 年年度经营业绩的具体情况，加强与投资者的互动交流，公司 拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 7 日（星期三）15：00-17： 00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登陆上 海证券报·中国证券网路演中心（https://roadshow.cnstock.com/ ）参与本次业绩说明会。 三、 参加 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company faced pressure on its annual performance in 2024, but there is a trend of improvement in Q4, supported by a rich reserve of amino acids that enhances competitiveness [1][6] - The company reported a revenue of 339 million yuan in 2024, a decrease of 12.9% year-on-year, with a net profit of 43 million yuan, down 19.8% year-on-year [6] - The company is actively expanding its special medical food and overseas raw material drug markets while continuing to enhance its amino acid product offerings through research and development [6] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 368 million yuan, with a projected net profit of 50 million yuan, reflecting a year-on-year growth of 16.7% [5][8] - The company’s gross margin is expected to be 29.4% in 2025, slightly down from 30.5% in 2024 [5] - The company plans to maintain a focus on R&D, with an estimated R&D expense of 32 million yuan by 2027, indicating a commitment to product development [5][6]

证券代码：836547 证券简称：无锡晶海 公告编号：2025-025 无锡晶海氨基酸股份有限公司 关于召开 2024 年年度股东大会通知公告（提供网络 投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 本次会议为 2024 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次会议的召集程序符合《中华人民共和国公司法》等有关法律、 法规、部门规章、其他规范性文件及《公司章程》的有关规定。会议 召开不需要相关部门批准或履行其他程序。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 同一表决权仅选择现场投票、网络投票中的一种方式，如同一表 决权出现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 一、 会议召开基本情况 （一）股东大会届次 2. 本公司董事、监事、高级管理人员。 3. 本公司聘请的律师。 本公司聘请的上海市广发律师事务所律师为见证律师。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简 称" ...

（一）会议召开情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 本次会议的召集、召开、议案审议程序符合有关法律法规、规范 性文件和《公司章程》的规定，所做决议合法有效。 证券代码：836547 证券简称：无锡晶海 公告编号：2025-024 （二）会议出席情况 1. 会议召开时间：2025 年 4 月 17 日 2. 会议召开地点：公司会议室 3. 会议召开方式：现场 4. 发出监事会会议通知的时间和方式：2025 年 4 月 7 日以电话方式 发出 5. 会议主持人：沈洪 6. 召开情况合法、合规、合章程性说明： 无锡晶海氨基酸股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 会议召开和出席情况 二、 议案审议情况 （一） 审议通过《关于公司 2024 年度审计报告的议案》 1.议案内容： 公司聘请上会会计师事务所（特殊普通合伙）对公司2024年12 月31日的资产负债表和2024年度的利润表、现金流量表、股东权益 变动表以及财务报表附注进行 ...

券代码：836547 证券简称：无锡晶海 公告编号：2025-023 无锡晶海氨基酸股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 会议召开和出席情况 2.议案表决结果：同意 6 票；反对 0 票；弃权 0 票。 议案已经公司第四届第三次审计委员会会议审议通过，同意将本 议案提交公司董事会审议。 （一）会议召开情况 本次会议的召集、召开、议案审议程序符合有关法律法规、规范 性文件和《公司章程》的规定，所做决议合法有效。 1.会议召开时间：2025 年 4 月 17 日 2.会议召开地点：公司会议室 3. 会议召开方式：现场 4. 发出董事会会议通知的时间和方式：2025 年 4 月 7 日以电话方式 发出 5.会议主持人：李松年 6. 会议列席人员：监事会主席沈洪、监事王丰、职工代表监事曹一 岗、财务总监兼董事会秘书陈向红 7.召开情况合法、合规、合章程性说明： （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、 议案审议情 ...